Creasallis is an antibody solutions company whose patented CreaTap modification can be incorporated into existing antibodies for cancer drug developers.
Creasallis was founded on the problem that antibody-based cancer drugs reach only a small fraction of a solid tumour, with penetration estimated between 0.001% and 7%. Its CreaTap technology applies a discrete set of mutations to an antibody's constant region so the molecule fragments inside the tumour microenvironment, and the technology is designed to be incorporated into existing monoclonal and bispecific antibodies.
Creasallis positions CreaTap against approaches that shrink antibodies into smaller fragments or inject drugs directly into tumours: the antibody stays large in circulation, avoiding kidney clearance, and breaks down only inside the tumour. The modification does not require a new discovery process, and partnerships with large pharmaceutical companies are an opportunity for the platform.